Table 4 Clinical characteristics in idiopathic pulmonary fibrosis patients by pirfenidone use since 2016
From: Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study
|  | Pirfenidone user (n = 5449) | Pirfenidone non-user (n = 7494) | p value |
|---|---|---|---|
Sex |  < 0.001 | ||
Men | 4312 (79.13%) | 5110 (68.19%) | Â |
Women | 1137 (20.87%) | 2384 (31.81%) | Â |
Age |  < 0.001 | ||
Older age (≥ 70 years) | 2300 (42.21%) | 2591 (34.57%) |  |
Younger age (< 70 years) | 3149 (57.79%) | 4903 (65.43%) |  |
Respiratory diseases | |||
COPD | 1893 (34.74%) | 2671 (35.64%) | 0.289 |
Lung cancer | 217 (3.98%) | 243 (3.24%) | 0.025 |
Pulmonary embolism | 72 (1.32%) | 150 (2.00%) | 0.003 |
Pulmonary hypertension | 45 (0.83%) | 133 (1.77%) |  < 0.001 |
Obstructive sleep apnoea | 29 (0.53%) | 24 (0.32%) | 0.062 |
Non-respiratory diseases | |||
GERD | 4272 (78.40%) | 5581 (74.47%) |  < 0.001 |
Dyslipidaemia | 3715 (68.18%) | 4944 (65.97%) | 0.008 |
Hypertension | 3193 (58.60%) | 4603 (61.42%) | 0.001 |
Diabetes mellitus | 2460 (45.15%) | 3495 (46.64%) | 0.093 |
Ischaemic heart disease | 1456 (26.72%) | 1989 (26.54%) | 0.820 |
Anxiety | 934 (17.14%) | 1601 (21.36%) |  < 0.001 |
Depression | 734 (13.47%) | 1228 (16.39%) |  < 0.001 |
Congestive heart failure | 726 (13.32%) | 1283 (17.12%) |  < 0.001 |
CCI |  < 0.001 | ||
0 | 170 (3.12%) | 178 (2.38%) | Â |
1 | 826 (15.16%) | 966 (12.89%) | Â |
2 | 1080 (19.82%) | 1376 (18.36%) | Â |
3 | 1030 (18.90%) | 1328 (17.72%) | Â |
≥ 4 | 2343 (43.00%) | 3646 (48.65%) |  |
CCI, mean (standard deviation) | 2.55 (2.53) | 2.51 (2.70) | 0.001 |